© Springer International Publishing Switzerland 2016Bruce Ovbiagele (ed.)Ischemic Stroke Therapeutics10.1007/978-3-319-17750-2_20 20. Selective Serotonin Reuptake Inhibitors Ali Saad1, 2 , Patrick Nguyen3 and Samir R. Belagaje4 (1) Vascular Neurology, Emory University Hospital, 1364 Clifton Rd NE, Atlanta, GA 30322, USA (2)…
Core components of CIMT 1. Restraint of the less affected upper extremity 2. Intense task-specific training and shaping therapy of the more affected upper extremity Enrollment in traditional CIMT has…
Outcome Result from pooled analyses: OR (95 % CI) or weighted mean difference (95 % CI) Death 0.79 (0.65, 0.98) Death and dependency 0.59 (0.49, 0.71) Need for institutionalization 0.69…
Primary hypercoagulable states Secondary hypercoagulable states Protein C deficiency Antiphospholipid antibody syndrome (Hughes syndrome) Protein S deficiency Protein C deficiency Factor V Leiden mutation Protein S deficiency Prothrombin gene 20210A…
Prevention Acute management General emergency management Treatment of the acute ischemic stroke itself Intravenous thrombolysis Endovascular interventions Prevention or treatment of acute complications Subsequent stroke management Prevention or treatment of…
© Springer International Publishing Switzerland 2016Bruce Ovbiagele (ed.)Ischemic Stroke Therapeutics10.1007/978-3-319-17750-2_15 15. Secondary Prevention After Symptomatic Large Artery Intracranial Disease Christine Anne Holmstedt1 , Alison P. Smock1 and Tanya N. Turan2 (1) Department of Neurology, Medical University of South Carolina, 96 Jonathon…
© Springer International Publishing Switzerland 2016Bruce Ovbiagele (ed.)Ischemic Stroke Therapeutics10.1007/978-3-319-17750-2_13 13. Secondary Prevention After Ischemic Lacunar Stroke Raffaella Valenti1 and Leonardo Pantoni2 (1) NEUROFARBA Department, Neuroscience Section, University of Florence, Florence, Italy (2) NEUROFARBA Department, Neuroscience…
Fig. 11.1 Possible mechanisms of stroke based on the medical records of Case #1 Risk of Stroke in Chronic Kidney Disease Patients Stroke is common in patients with end-stage kidney…
© Springer International Publishing Switzerland 2016Bruce Ovbiagele (ed.)Ischemic Stroke Therapeutics10.1007/978-3-319-17750-2_10 10. Heterogeneous Causes of Stroke: Antithrombotics Atul Ashok Kalanuria1 and Geoffrey Ling2 (1) Division of Neurocritical Care, University of Pennsylvania School of Medicine, Philadelphia, PA, USA (2)…
© Springer International Publishing Switzerland 2016Bruce Ovbiagele (ed.)Ischemic Stroke Therapeutics10.1007/978-3-319-17750-2_9 9. Traditional Stroke Risk Factor Treatment Shelly Ozark1 and Bruce Ovbiagele2 (1) Department of Neurology, Medical University of South Carolina, 96 Jonathan Lucas St, Suite 301…
